Compare iShares Core S&P 500 ETF (IVV) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core S&P 500 ETF vs Sana Biotechnology Inc — how do they compare? iShares Core S&P 500 ETF trades at $781.9 (market cap $897.20B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: iShares Core S&P 500 ETF is far larger — about 1072.3× Sana Biotechnology Inc's market cap, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core S&P 500 ETF for 46 Days and Sana Biotechnology Inc for 23 Days on average.
| IVV | SANA | |
|---|---|---|
Market Cap | $897.20B | $836.71M |
Volume | 4,580,672 | 4,507,444 |
Sector | Broad Market / Factor | Health |
52-Week High | $782.58 | $5.92 |
52-Week Low | $634.93 | $2.68 |
Typical Hold Time | 46 Days | 23 Days |
Enterprise Value | — | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IVV, tracking the S&P 500, trades at $782.06, up 0.19% with a bullish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at 68.88 suggesting mild overbought conditions. Recent news highlights S&P 500 valuation debates, with earnings growth expected to slow from 35% in 2026 to 15% in 2027 according to Wall Street analysts (24/7 Wall Street, 2026-10-03).
The outlook remains cautiously optimistic with seasonal patterns favoring year-end rallies, though concentration risks in top holdings and slowing profit growth present headwinds. Key support at $775 and resistance at $780 will dictate near-term direction as investors monitor economic data and Federal Reserve policy.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
